2018 ESC/ESH Guidelines for the management of arterial hypertension

This is not a single experiment but a clinical practice guideline — a systematic synthesis of all available randomised controlled trial (RCT) evidence, observational studies, and meta-analyses on hypertension diagnosis, treatment thresholds, and management strategies. The guideline committee evaluated:

**Diagnostic thresholds:** What blood pressure (BP) level defines hypertension and when to start treatment.

**Treatment targets:** What BP level to aim for once treatment begins (e.g., systolic <140 mmHg vs. <130 mmHg vs. <120 mmHg).

**Drug classes:** Which antihypertensive medications work best as first-line, second-line, and combination therapy.

**Lifestyle interventions:** The effect size of salt reduction, exercise, weight loss, alcohol moderation, and dietary changes on BP.

**Monitoring strategies:** Whether clinic BP, home BP monitoring, or 24-hour ambulatory BP monitoring (ABPM) better predicts cardiovascular outcomes.

The primary outcome across the underlying trials was a composite of cardiovascular death, myocardial infarction, stroke, and heart failure. Secondary outcomes included all-cause mortality, renal function decline, and adverse events from medications.

The guidelines are based on evidence from dozens of major RCTs and meta-analyses involving hundreds of thousands of participants. Key trials informing the recommendations include:

**SPRINT trial (2015):** 9,361 adults aged ≥50 years with systolic BP ≥130 mmHg and at least one cardiovascular risk factor, but excluding people with diabetes or prior stroke.

**ACCORD-BP trial (2010):** 4,733 adults with type 2 diabetes and systolic BP 130–180 mmHg.

**HYVET trial (2008):** 3,845 adults aged ≥80 years with systolic BP ≥160 mmHg.

**HOPE-3 trial (2016):** 12,705 adults with intermediate cardiovascular risk (no prior cardiovascular disease) and systolic BP 130–160 mmHg.

**Multiple meta-analyses** including the Blood Pressure Lowering Treatment Trialists' Collaboration (BPLTTC), which pooled data from over 350,000 participants across 48 RCTs.

The population covered adults aged 18–90+ years, with and without diabetes, chronic kidney disease, or prior cardiovascular events. The guidelines explicitly note that evidence is weaker for adults under 40 and for those with frailty or multimorbidity.

The guidelines rely on standardised BP measurement protocols:

**Clinic BP:** Measured with a validated automated oscillometric device after 5 minutes of seated rest, with the arm supported at heart level, using an appropriately sized cuff. Three readings taken 1–2 minutes apart, averaged.

**Home BP monitoring (HBPM):** Patients measure BP twice daily (morning and evening) for at least 3–7 days, using validated devices. Morning readings taken after voiding, before medication, and before breakfast. Evening readings taken before bedtime.

**24-hour ambulatory BP monitoring (ABPM):** A portable device takes BP every 15–30 minutes during the day and every 30–60 minutes at night over 24 hours. This captures nocturnal BP dipping, morning surge, and white-coat effects.

**Outcome measurement:** Cardiovascular events (heart attack, stroke, heart failure hospitalisation, cardiovascular death) were adjudicated by blinded committees in the underlying trials. BP was measured using the same standardised protocols.

### Study design

This is a **clinical practice guideline**, not a primary research study. The methodology follows the GRADE (Grading of Recommendations, Assessment, Development, and Evaluations) framework. The guideline committee:

1. **Systematically reviewed** all available RCTs, meta-analyses, and observational studies published up to 2018.

2. **Graded the quality of evidence** for each recommendation (high, moderate, low, very low) based on study design, risk of bias, consistency, directness, and precision.

3. **Formulated recommendations** as "strong" (benefits clearly outweigh harms) or "weak" (benefits and harms are closely balanced), with the strength linked to the evidence grade.

### What this design can and cannot prove

**What it can prove:**

The guidelines can identify which interventions have the strongest evidence base from large, well-conducted RCTs.

They can provide effect size estimates that are generalisable to broad populations (e.g., "reducing systolic BP by 10 mmHg reduces major cardiovascular events by ~20%").

They can flag areas where evidence is weak or absent (e.g., optimal targets for frail elderly patients).

**What it cannot prove:**

Guidelines cannot prove causality for individual patients — they summarise population averages.

They cannot account for individual genetic, metabolic, or lifestyle variations that might change the risk-benefit ratio of a specific drug or target.

They are inherently conservative — recommendations lag behind the latest evidence because they require multiple confirmatory trials.

The guideline process involves expert opinion where evidence is lacking, which introduces subjective bias.

### Major methodological considerations

**Conflict of interest:** Guideline committee members disclosed relationships with pharmaceutical companies. While the ESC/ESH have conflict-of-interest policies, industry influence on guideline recommendations is a well-documented concern.

**Evidence gaps:** Many recommendations are based on extrapolation from trials that excluded older, frailer, or multimorbid patients. The guidelines explicitly note that "the evidence base for treatment in the very elderly (≥80 years) is limited."

**Publication bias:** Trials with positive results are more likely to be published and included in meta-analyses, potentially inflating effect sizes.

**Time lag:** The guidelines were published in 2018. Subsequent trials (e.g., the 2021 STEP trial in China, the 2020 BPLTTC meta-analysis) have since provided additional evidence that may shift recommendations.

### Diagnostic thresholds

**Normal BP:** Systolic <120 mmHg and diastolic <80 mmHg

**High-normal BP:** Systolic 120–129 mmHg and/or diastolic 80–84 mmHg

**Grade 1 hypertension:** Systolic 130–139 mmHg and/or diastolic 85–89 mmHg

**Grade 2 hypertension:** Systolic 140–179 mmHg and/or diastolic 90–109 mmHg

**Grade 3 hypertension:** Systolic ≥180 mmHg and/or diastolic ≥110 mmHg

**Isolated systolic hypertension:** Systolic ≥140 mmHg with diastolic <90 mmHg (common in older adults)

### Treatment initiation thresholds

**For most adults aged 18–79:** Start drug treatment when systolic BP is ≥140 mmHg or diastolic ≥90 mmHg, regardless of cardiovascular risk level.

**For adults with high cardiovascular risk** (established cardiovascular disease, diabetes, chronic kidney disease, or a 10-year cardiovascular risk score ≥10%): Consider starting drug treatment when systolic BP is 130–139 mmHg.

**For adults aged ≥80 years:** Start drug treatment when systolic BP is ≥160 mmHg.

### Treatment targets

**Primary target for most adults:** Systolic BP 120–129 mmHg (not <140 mmHg as in previous guidelines).

**For adults aged ≥80 years:** Systolic BP target 130–139 mmHg.

**For adults with diabetes:** Systolic BP target 120–129 mmHg (same as general population — a change from earlier guidelines that recommended <130/80 mmHg).

**For adults with chronic kidney disease:** Systolic BP target 120–129 mmHg.

### Drug therapy

**First-line drugs (five classes):** ACE inhibitors (e.g., ramipril, lisinopril), angiotensin receptor blockers (ARBs, e.g., losartan, valsartan), calcium channel blockers (CCBs, e.g., amlodipine), thiazide/thiazide-like diuretics (e.g., chlorthalidone, indapamide), and beta-blockers (e.g., bisoprolol, atenolol — but only for specific indications like heart failure, angina, or post-myocardial infarction).

**Preferred first-line combination:** An ACE inhibitor or ARB plus a CCB or thiazide diuretic. This combination is more effective than either drug alone and has fewer side effects than high-dose monotherapy.

**Single-pill combinations** are recommended to improve adherence (taking one pill instead of two or three).

**Beta-blockers** are no longer first-line for uncomplicated hypertension (unless the patient has heart failure, angina, or a prior heart attack).

### Lifestyle interventions (effect sizes from meta-analyses)

**Salt reduction:** Reducing sodium intake by ~2 g/day (from ~4 g/day to ~2 g/day) lowers systolic BP by 4–6 mmHg in people with hypertension.

**Weight loss:** Each 1 kg of weight loss reduces systolic BP by ~1 mmHg. A 5 kg weight loss reduces systolic BP by ~5 mmHg.

**Exercise:** 150 minutes/week of moderate-intensity aerobic exercise (e.g., brisk walking) reduces systolic BP by 5–8 mmHg.

**DASH diet:** The Dietary Approaches to Stop Hypertension diet (rich in fruits, vegetables, low-fat dairy, whole grains, and low in saturated fat) reduces systolic BP by 6–11 mmHg in people with hypertension.

**Alcohol reduction:** Reducing alcohol intake from heavy drinking (≥3 drinks/day) to moderate drinking (≤2 drinks/day for men, ≤1 for women) reduces systolic BP by 3–5 mmHg.

**Potassium supplementation:** Increasing dietary potassium (from fruits, vegetables, or supplements) reduces systolic BP by 3–5 mmHg in people with hypertension.

### Monitoring

**Home BP monitoring** is recommended for all patients on treatment, with readings taken twice daily for 3–7 days before each clinic visit.

**24-hour ABPM** is recommended for diagnosing white-coat hypertension (elevated clinic BP but normal out-of-office BP) and masked hypertension (normal clinic BP but elevated out-of-office BP).

**White-coat hypertension** affects 15–30% of people with elevated clinic BP. These individuals have lower cardiovascular risk than sustained hypertensives but higher risk than normotensives.

**Masked hypertension** affects 10–20% of people with normal clinic BP. These individuals have cardiovascular risk similar to sustained hypertensives.

The guidelines translate the trial evidence into practical numbers:

**Reducing systolic BP by 10 mmHg** (from any starting level) reduces the risk of major cardiovascular events by ~20%, coronary heart disease by ~17%, stroke by ~27%, and heart failure by ~28%. This effect is consistent across age groups, sexes, and baseline BP levels.

**Intensive vs. standard treatment** (target <120 mmHg vs. <140 mmHg in SPRINT): Intensive treatment reduced major cardiovascular events by 25% (hazard ratio 0.75, 95% CI 0.64–0.89, p<0.001) and all-cause mortality by 27% (HR 0.73, 95% CI 0.60–0.90, p=0.003). However, intensive treatment also increased serious adverse events: hypotension (2.4% vs. 1.4%), syncope (2.3% vs. 1.7%), electrolyte abnormalities (3.1% vs. 2.3%), and acute kidney injury (4.1% vs. 2.5%).

**Number needed to treat (NNT):** For intensive vs. standard treatment over 3.3 years, the NNT to prevent one major cardiovascular event was 61. For all-cause mortality, the NNT was 90. This means 61 people need to be treated intensively for 3.3 years to prevent one heart attack, stroke, or cardiovascular death.

**Number needed to harm (NNH):** For serious adverse events, the NNH was 50–100 depending on the specific event. The benefit-risk ratio is favourable for most patients but narrows for those at low cardiovascular risk.

### What the authors acknowledge

The evidence base is strongest for adults aged 50–79 with moderate-to-high cardiovascular risk. Evidence is weaker for younger adults, the very elderly, and those with frailty or multimorbidity.

The SPRINT trial used automated office BP measurement (patient alone in a quiet room, device taking multiple readings without a clinician present), which gives readings 5–10 mmHg lower than standard clinic BP. This means the 120 mmHg target in SPRINT corresponds to approximately 125–130 mmHg in routine clinical practice.

The guidelines are based on evidence available up to 2018. Subsequent trials (e.g., STEP 2021) have since provided additional data on intensive targets in older adults.

The recommendations for drug combinations are based on expert consensus where head-to-head trials are lacking.

### What a critical reader would note

**Industry ties:** Many guideline authors have financial relationships with pharmaceutical companies that manufacture antihypertensive drugs. While disclosed, the potential for subtle bias in drug class recommendations is real.

**Population limits:** The SPRINT trial excluded people with diabetes, prior stroke, heart failure, or eGFR <20 mL/min/1.73m². The ACCORD trial (which found no benefit of intensive targets in diabetes) had different results. The guidelines extrapolate SPRINT findings to these populations despite the exclusion.

**Side effect underreporting:** In SPRINT, the intensive group had more hypotension, syncope, and acute kidney injury. In real-world practice, with less monitoring, these rates could be higher.

**Adherence assumptions:** The guidelines assume patients will adhere to complex multi-drug regimens. Real-world adherence to antihypertensives is ~50% at one year. The guidelines' recommendations may not be achievable for many patients.

**Cost and access:** The guidelines do not discuss the cost of single-pill combinations, which are often more expensive than separate pills. This may limit access for lower-income populations.

**Lifestyle recommendations are aspirational:** The effect sizes for lifestyle changes come from supervised trials with high adherence. Real-world adherence to salt reduction, weight loss, and exercise is much lower, and the actual BP reductions are typically smaller.

For someone running their own n=1 experiment to manage blood pressure:

### What to test

**Lifestyle first:** Test the DASH diet (rich in fruits, vegetables, low-fat dairy, whole grains; low in saturated fat, red meat, and added sugar) combined with sodium restriction to <2,000 mg/day. This is the single most effective non-drug intervention, with expected systolic BP reduction of 6–11 mmHg.

**Exercise protocol:** Test 150 minutes/week of moderate-intensity aerobic exercise (brisk walking, cycling, swimming) in sessions of at least 30 minutes. Expected systolic BP reduction: 5–8 mmHg.

**Weight loss if overweight:** Test a calorie deficit of 500–750 kcal/day targeting 0.5–1 kg/week weight loss. Expected systolic BP reduction: ~1 mmHg per kg lost.

**If lifestyle is insufficient:** Test a single-pill combination of an ACE inhibitor or ARB plus a CCB or thiazide diuretic (e.g., lisinopril 10 mg + amlodipine 5 mg). This is the guideline-recommended first-line drug approach.

### Minimum meaningful duration

**Lifestyle interventions:** 4–8 weeks to see the full BP-lowering effect. The DASH diet shows measurable BP reduction within 2 weeks, but maximal effect takes 4–6 weeks.

**Drug therapy:** 2–4 weeks for the full effect of most antihypertensives. Dose adjustments should be made at 2–4 week intervals.

**Weight loss:** 8–12 weeks to see meaningful BP changes from weight loss (assuming 5–10 kg loss).

### What to measure

**Primary metric:** Systolic and diastolic BP measured at home using a validated automated oscillometric device (check the device against the STRIDE BP or dablEducational Trust validation lists). Measure twice daily: morning (after voiding, before medication, before